The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
We are building an AI-native operating system for pharma sales and distribution
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
Shashwat Goenka takes over as Vice President of industry body
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Subscribe To Our Newsletter & Stay Updated
